Company Analysis ICU Medical
1. Summary
Advantages
- The stock's return over the last year (-21.17%) is higher than the sector average (-43.8%).
- The company's current efficiency (ROE=-5.76%) is higher than the sector average (ROE=-73.93%)
Disadvantages
- Price (123.48 $) is higher than fair price (68.74 $)
- Dividends (0%) are below the sector average (1.36%).
- Current debt level 39.05% has increased over 5 years from 2.14%.
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| ICU Medical | Healthcare | Index | |
|---|---|---|---|
| 7 days | 2% | -12.7% | 2.3% |
| 90 days | -3.7% | -28.9% | 4.3% |
| 1 year | -21.2% | -43.8% | 14.4% |
ICUI vs Sector: ICU Medical has outperformed the "Healthcare" sector by 22.62% over the past year.
ICUI vs Market: ICU Medical has significantly underperformed the market by -35.57% over the past year.
Stable price: ICUI is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: ICUI with weekly volatility of -0.4072% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Above fair price: The current price (123.48 $) is higher than the fair price (68.74 $).
Price is higher than fair: The current price (123.48 $) is 44.3% higher than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (-23.65) is lower than that of the sector as a whole (28.54).
P/E vs Market: The company's P/E (-23.65) is lower than that of the market as a whole (55.86).
5.3. P/BV
P/BV vs Sector: The company's P/BV (1.91) is lower than that of the sector as a whole (10.22).
P/BV vs Market: The company's P/BV (1.91) is lower than that of the market as a whole (17.51).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (1.58) is lower than that of the sector as a whole (4.26).
P/S vs Market: The company's P/S indicator (1.58) is lower than that of the market as a whole (27.76).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (118.56) is higher than that of the sector as a whole (18.11).
EV/Ebitda vs Market: The company's EV/Ebitda (118.56) is higher than that of the market as a whole (32.47).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -47.1% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-47.1%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (0.1718%).
6.4. ROE
ROE vs Sector: The company's ROE (-5.76%) is higher than that of the sector as a whole (-73.93%).
ROE vs Market: The company's ROE (-5.76%) is lower than that of the market as a whole (38.91%).
6.6. ROA
ROA vs Sector: The company's ROA (-2.74%) is lower than that of the sector as a whole (6.84%).
ROA vs Market: The company's ROA (-2.74%) is lower than that of the market as a whole (11.35%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (21.56%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (10.27%).
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.36%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.67.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
9. Insider trades
9.1. Insider trading
Insider Selling More insider purchases by 100% over the last 3 months.
9.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 25.11.2025 | Woolson Daniel VP, GM-Infusion Capital |
Sale | 152.35 | 44 136 | 2 897 |
| 14.08.2025 | Jain Vivek Chairman and CEO |
Purchase | 112.84 | 2 474 470 | 21 929 |
| 13.05.2025 | Greenberg David C. Director |
Sale | 143.66 | 278 988 | 1 942 |
| 13.05.2025 | Greenberg David C. Director |
Purchase | 50.17 | 183 873 | 3 665 |
| 13.05.2025 | Hernandez Laurie Director |
Purchase | 143.59 | 247 406 | 1 723 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
Based on sources: porti.ru
